Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Tumour Registry Breast Cancer (TMK)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):
iOMEDICO AG
ClinicalTrials.gov Identifier:
NCT01351584
First received: May 9, 2011
Last updated: February 27, 2017
Last verified: February 2017

May 9, 2011
February 27, 2017
February 2007
June 2019   (Final data collection date for primary outcome measure)
Course of Antineoplastic Treatment [ Time Frame: 5 years ]
Course of Antineoplastic Treatment [ Time Frame: 3 years ]
Complete list of historical versions of study NCT01351584 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Tumour Registry Breast Cancer
Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany
The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice of office-based and clinic-based medical oncologists in Germany.

The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record information on the antineoplastic treatment of breast cancer in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, biomarker testing and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the multiple patient-reported outcomes (MaLife).

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Breast cancer patients undergoing antineoplastic or antihormonal therapy.
Breast Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4500
December 2020
June 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Breast cancer
  • 18 years and older
  • Antineoplastic or antihormonal treatment

Exclusion Criteria:

  • No breast cancer
  • Below 18 years
  • No antineoplastic or antihormonal treatment
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Germany
 
NCT01351584
IOM TMK
Tumorregister Mammakarzinom ( Other Identifier: iOMEDICO AG )
No
Not Provided
No
Not Provided
iOMEDICO AG
iOMEDICO AG
  • Arbeitskreis Klinische Studien
  • Arbeitsgemeinschaft fur Internistische Onkologie
Study Chair: Hans Tesch, MD
iOMEDICO AG
February 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP